NCT03309800已完成2 期
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 168
- 试验地点
- 1
- 主要终点
- Bronchitis Severity Total Score(BSS) Change
研究概览
简要总结
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HL301 versus Placebo in acute bronchitis patients.
Endpoint: BSS, The improvement and improvement rate of the tester for the treatment response, The satisfaction of the subject, Total usage of Acetaminophen
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Both gender, 19 years ≤ age ≤ 80 years
- •(Bronchitis Severity Score)* ≥ 5point at Visit 2 (Randomized Visit)
- •Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)
- •Those who can comply with the requirements of clinical trials
- •Written consent voluntarily to participate in this clinical trial
排除标准
- •Patients with respiratory and systemic infections requiring systemic antibiotic therapy
- •Patients with bleeding tendency
- •Patients who investigators determines to severe respiratory disease that would interfere with study assessment
- •Patients who were treated with oral systemic adrenocortical hormone or immunosuppressive drug within 4 weeks prior to Visit 2
- •Patients who were treated with oral antihistamines, ACE suppressive. or systemic/inhalative glucocorticosteroid within 2 weeks prior to Visit 2
研究组 & 干预措施
Experimental
Experimental
HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
干预措施: HL301 (Drug)
Placebo comparator
Placebo Comparator
HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
干预措施: HL301(Placebo) (Drug)
结局指标
主要结局
Bronchitis Severity Total Score(BSS) Change
时间窗: Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)
Evaluation period: Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)
次要结局
- The improvement and improvement rate of the tester for the treatment response (Chi-square test or Fisher's Exact test)(Visit 3 (7 day))
- The satisfaction of the subject (Questionnaire)(Visit 3 (7 day))
- Total usage of Acetaminophen(Visit 3 (7 day))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASHNON-ALCOHOLIC STEATOHEPATITISNCT06054815NeuroBo Pharmaceuticals Inc.109
已完成
2 期
Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute BronchitisAcute BronchitisNCT02637310PharmaKing108
已完成
2 期
A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)Atopic DermatitisNCT04530643Shaperon80
暂停
2 期
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced DyskinesiaDyskinesiasMovement DisordersCentral Nervous System DiseasesNervous System DiseasesNeurologic ManifestationsNCT04912115PharmaTher Inc.30
Unknown
2 期
A Study of TG103 Injection in Overweight or ObesityOverweight or ObesityNCT05299697CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.195